Prabirkumar Bandyopadhyay

PubMed2006

Cardiovascular disease and diabetes mellitus: highlights from the Annual Professional Conference of Diabetes UK.

Diabetes UK held its Annual Professional Conference on March 29-31, 2006, in Birmingham, United Kingdom. This conference aimed to deliver the latest global developments in diabetes care using basic and clinical science as its cornerstone, and to inspire and support innovation in current practice. This report will examine the advances in different aspects of cardiovascular disease in diabetes mellitus.

Journal Article↗

PubMed2006

Drug-induced hyperprolactinemia.

Hyperprolactinemia is the most common biochemical abnormality currently encountered in clinical endocrinology. Hyperprolactinemic syndromes are a diverse group of disorders that are common in both men and women. Once the diagnosis of hyperprolactinemia has been established, the patient should be screened for the numerous causes of hormone hypersecretion. Hence, an accurate medical history is extremely important for the clinician to find out the most frequent causes of hypersecretion of prolactin (e.g., drugs). Clinicians should be aware of the possibility of prolactin elevation and associated problems with any drug that has the potential to cause hyperprolactinemia, particularly in patients who have other factors that might stimulate prolactin release.

Journal Article↗

PubMed2006

Drug-induced hyperprolactinemia.

Hyperprolactinemia is the most common biochemical abnormality currently encountered in clinical endocrinology. Hyperprolactinemic syndromes are a diverse group of disorders that are common in both men and women. Once the diagnosis of hyperprolactinemia has been established, the patient should be screened for the numerous causes of hormone hypersecretion. Hence, an accurate medical history is extremely important for the clinician to find out the most frequent causes of hypersecretion of prolactin (e.g., drugs). Clinicians should be aware of the possibility of prolactin elevation and associated problems with any drug that has the potential to cause hyperprolactinemia, particularly in patients who have other factors that might stimulate prolactin release.

Drug-Related Side Effects and Adverse Reactions↗

PubMed2006

Novel therapies in diabetes mellitus.

The 42nd annual meeting of the European Association for the Study of Diabetes (EASD) was held in Copenhagen-Malmo, September 14-17, 2006. This scientific program brought together international panels of speakers who discussed recent advances in epidemiology, genetics, pathophysiology and emerging therapeutic strategies in diabetes mellitus and related disorders. This article focuses on a broad range of new therapeutic possibilities and advances in the management of diabetes mellitus.

Caloric Restriction↗

PubMed2005

Recent developments in cardiovascular disease in diabetes mellitus: 41st annual meeting of the European Association for the Study of Diabetes.

September 10-15, 2005, the European Association for the Study of Diabetes held its 41st Annual Meeting in Athens, Greece. This meeting was devoted to new developments in understanding, diagnosis and management of diabetes mellitus and related disorders. Each day's program included plenary sessions, symposia, oral presentations, poster discussions, lectures, current issues and supportive care. This article highlights recent developments in pathophysiology, new therapeutic possibilities and preventive aspects of cardiovascular diseases in diabetes mellitus.

Cardiovascular Diseases↗

PubMed2005

Advances in the understanding of cardiovascular disease in diabetes mellitus: highlights from the Annual Professional Conference of Diabetes UK.

April 20-22, 2005, Diabetes UK held its annual conference in Glasgow, United Kingdom. The meeting brought together investigators, clinicians, professionals and policy makers interested in the field of diabetes. This report will examine the advances in understanding the risk factors, epidemiology, risk reduction and management of cardiovascular disease and lipid abnormalities in diabetic patients.

Cardiovascular Diseases↗

PubMed2005

Recent developments in cardiovascular disease in diabetes mellitus.

September 10-15, 2005, the European Association for the Study of Diabetes held its 41st Annual Meeting in Athens, Greece. This meeting was devoted to new developments in understanding, diagnosis and management of diabetes mellitus and related disorders. Each day's program included plenary sessions, symposia, oral presentations, poster discussions, lectures, current issues and supportive care. This article highlights recent developments in pathophysiology, new therapeutic possibilities and preventive aspects of cardiovascular diseases in diabetes mellitus.

Adolescent↗

PubMed2004

Recent developments in lipid-lowering therapy. Highlights from the Atorvastatin Landmark Program: Global Investigators Meeting III. June 1-3, 2004. Toronto, Canada.

The Atorvastatin Landmark Program: Global Investigators Meeting III was held June 1-3, in Toronto, Canada. The purpose of the meeting was to update investigators on the current status of the clinical trials that encompass the Atorvastatin Landmark Program. The main objectives were the following: 1. To review the range of studies that comprise the Atorvastatin Landmark Program. 2. To communicate recently completed study results and discuss the current and future impact of the findings, both individually and collectively, on clinical practice and guideline recommendations. 3. To discuss how the program is anticipated to evolve, highlighting new therapeutic modalities.

Anticholesteremic Agents↗

PubMed2004

Advances in the understanding of diabetes mellitus.

The American Diabetic Association held its 64th Scientific Sessions on June 4-8, 2004, in Orlando, Florida, USA. The meeting was devoted to developments in different areas of diabetes mellitus research: epidemiology; understanding of diabetic microvascular and macrovascular complications; various modes of treatment including complementary and alternative medicine; new targets in the treatment of the disease, including islet cell transplantation; and the approach to the concept of good quality of care.

Diabetes Mellitus↗

PubMed2004

Advancement of knowledge in the field of diabetes mellitus and related metabolic diseases.

The European Association for the Study of Diabetes held its 40th annual meeting September 5-9, 2004, in Munich, Germany. This scientific program presented the results of extensive research on various issues of diabetes and the related disorders, which gave a broader insight into the pathophysiology of the metabolic process. It also focused on a broad range of new therapeutic possibilities and advances in the management of diabetes and its complications.

Adult↗

PubMedDate not supplied

Cardiovascular diseases and diabetes mellitus.

Diabetes UK held its Annual Professional Conference on March 29-31, 2006, in Birmingham, United Kingdom. This conference aimed to deliver the latest global developments in diabetes care using basic and clinical science as its cornerstone, and to inspire and support innovation in current practice. This report will examine the advances in different aspects of cardiovascular disease in diabetes mellitus.

Angiotensin-Converting Enzyme Inhibitors↗